First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Xinan Sheng, Yi He et al.|The Lancet Oncology|2025Cited by 10